

Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme

Camilo E. Fadul · Patrick Y. Wen ·
Lyndon Kim · Jeffrey J. Olson

Published online: 8 January 2009
© Springer Science+Business Media, LLC. 2009

Erratum to: J Neurooncol (2008) 89:339–357
DOI 10.1007/s11060-008-9615-4

In Table 3 (p. 353) of the original publication, survival data for the glioblastoma subgroups of the Westphal et al. (Neuro Oncol, 2003) and Valtonen et al. (Neurosurgery, 1997) studies refer to “mean” survival. These data are

actually “median” survival. In the text, the data are correctly presented as “median” survival (see p. 352 of the original publication).

The online version of the original article can be found under doi:[10.1007/s11060-008-9615-4](https://doi.org/10.1007/s11060-008-9615-4).

C. E. Fadul
Neuro-Oncology Program, Norris Cotton Cancer Center,
Dartmouth Hitchcock Medical Center, Dartmouth Medical
School, Lebanon, NH, USA

P. Y. Wen
Center for Neuro-Oncology, Dana Farber/Brigham and
Women’s Cancer Center and Department of Neurology,
Brigham and Women’s Hospital, Boston, MA, USA

L. Kim
Neuro-oncology Branch, NCI, National Institutes of Health,
Bethesda, MD, USA

J. J. Olson (✉)
Department of Neurosurgery, Emory University School
of Medicine, 1365B Clifton Rd., NE, Ste. 6200, Atlanta,
GA 30322, USA
e-mail: jeffrey.olson@emoryhealthcare.org